United States - English - NLM (National Library of Medicine)

bioactive nutritionals, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), pregnenolone (unii: 73r90f7mq8) (pregnenolone - unii:73r90f7mq8), progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - for temporary relief of stressful situations, lowered immune response, inflammation processes, enhances calcium metabolism in bones, improves moods, and enhances cell metabolism. for temporary relief of stressful situations, lowered immune response, inflammation processes, enhances calcium metabolism in bones, improves moods, and enhances cell metabolism.

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), pregnenolone (unii: 73r90f7mq8) (pregnenolone - unii:73r90f7mq8), progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y), testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - for temporary relief of symptoms due to male andropause such as:  lethargy, muscle weakness & aches, and decrease in libido. for temporary relief of symptoms due to male andropause such as: lethargy, muscle weakness & aches, and decrease in libido.

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), pregnenolone (unii: 73r90f7mq8) (pregnenolone - unii:73r90f7mq8), progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y), testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - for temporary relief of symptoms due to menopausal hot flashes, loss of libido; may enhance calcium metabolism, feelings of well-being and mental clarity. for temporary relief of symptoms due to menopausal hot flashes, loss of libido; may enhance calcium metabolism, feelings of well-being and mental clarity.

United States - English - NLM (National Library of Medicine)

bioactive nutritional, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), sus scrofa pituitary gland (unii: l0pfemq1dt) (sus scrofa pituitary gland - unii:l0pfemq1dt), pregnenolone (unii: 73r90f7mq8) (pregnenolone - unii:73r90f7mq8), progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y), bos taurus spleen (unii: 190q9mb3u3) (bos taurus spleen - unii:190q9mb3u3), testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o), sus scrofa thym - prasterone 8 [hp_x] in 1 ml - for temporary relief of weakness after flu or viral infection, for fortifying spleen and thymus and general revitalization. for temporary relief of weakness after flu or viral infection, for fortifying spleen and thymus and general revitalization.

United States - English - NLM (National Library of Medicine)

health science funding, llc - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - prasterone 200 mg - oral prasterone (200mg per day) in female patients with active systemic lupus erythematosus (sle) has in several blinded, placebo-controlled randomized clinical studies been associated with a reduced risk of auto-immune flare, §§6.2, 14.1.1, a reduced risk of breast cancer and a reduced risk of death from any cause, §§6.4, 14.2. patients with sle may have depressed serum levels of 5-dehydroepiandrosterone sulfate (5-dheas). oral prasterone has been shown to restore sle patients' serum 5-dheas levels. prastera® oral softgels are intended for use in patients for whom medical evaluation shows a depressed serum level of dhea and thus a distinctive need for exogenous dhea. prastera® oral prasterone softgels are intended to be used under medical supervision, for a patient receiving active and ongoing medical supervision, wherein the patient obtains medical care on a recurring basis for, among other things, instructions on the use of this product. prastera® oral prasterone softgels are intended for the dietary m

United States - English - NLM (National Library of Medicine)

amag pharmaceuticals, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - prasterone 6.5 mg - intrarosa® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. undiagnosed abnormal genital bleeding: any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with intrarosa. risk summary intrarosa is indicated only in postmenopausal women. there are no data with intrarosa use in pregnant women regarding any drug-associated risks. animal reproduction studies have not been conducted with prasterone. risk summary intrarosa is indicated only in postmenopausal women. there is no information on the presence of prasterone in human milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness have not been established in pediatric patients. of the 1522 prasterone-treated postmenopausal women enrolled in the four placebo-controlled 12-week and one open-label 52-week clinical t

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - prasterone - oral capsule - 75mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - prasterone - oral tablet - 25mg

United States - English - NLM (National Library of Medicine)

millicent us, inc. - prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b) - intrarosa ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. undiagnosed abnormal genital bleeding: any postmenopausal woman with undiagnosed, persistent or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment with intrarosa. risk summary intrarosa is indicated only in postmenopausal women. there are no data with intrarosa use in pregnant women regarding any drug-associated risks. animal reproduction studies have not been conducted with prasterone. risk summary intrarosa is indicated only in postmenopausal women. there is no information on the presence of prasterone in human milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness have not been established in pediatric patients. of the 1522 prasterone-treated postmenopausal women enrolled in the four placebo-controlled 12-week and one open-label 52-week clinic

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - prasterone, quantity: 6.5 mg - pessary - excipient ingredients: hard fat - intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.